FDA Approves Cochlear Implantation for Single-Sided Deafness
Single-sided deafness (SSD) can create difficulties for people localizing sound and listening in the noisy situations. This can lead to negative impacts on communication and socialization. SSD can be caused by viral infections, head trauma, Meniere’s Disease, or have an unknown cause. Treatment options have been limited, with cochlear implants typically reserved for people with severe to profound hearing loss in both ears.
On July 22, 2019, Med-El USA, a manufacturer of cochlear implants, announced that the Food & Drug administration approved their cochlear implant for people 5 years and older with profound hearing loss in one ear and normal to mild hearing loss in the other. Research supporting the approval shows that SSD participants had improvements in speech understanding in quiet and noise, and improvements in sound localization when they obtained the cochlear implant.
Cochlear implantation still requires certain testing and considerations, but is a step forward for the treatment of single-sided hearing loss.